TransCode Therapeutics Receives $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate Page 1

Grant awarded by the National Cancer Institute (NCI) of the NIH to support the clinical development of the lead therapeutic candidate, TTX-MC138

BOSTON, Sept. 5, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapies, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support the clinical evaluation of TTX-MC138, TransCode’s lead therapeutic candidate. TransCode recently activated three clinical trial sites to conduct a Phase I/II clinical trial of TTX-MC138 for the treatment of advanced solid tumors.